A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
Recruiting · NCT07000617 · Registry updated 2025-06-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma | Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, lymphoma, neoplasm | Recruiting | Phase 2 | 2025-06-03 | NCT07000617 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese Academy of Medical Sciences | 36 |
| Peking University Cancer Hospital & Institute | 189 |
| Peking University International Hospital | 26 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing | China | 1 |
| Peking University Cancer Hospital | Beijing | China | 21 |
| Peking University International Hospital | Beijing | China | 7 |